Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00639405
Other study ID # SUNYUMU 5260
Secondary ID
Status Terminated
Phase N/A
First received March 12, 2008
Last updated April 26, 2011
Start date September 2005
Est. completion date August 2008

Study information

Verified date October 2008
Source State University of New York - Upstate Medical University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

The purpose of this study is to design a method to better localize parathyroid adenomas. This study will include approximately 6 patients who have not had surgery and another 25 patients who have already had surgery over the course of one year.


Description:

While a successful neck exploration for PHP is primarily dependent on the experience of the surgeon, there are currently several localizing studies available to increase success. Although the necessity of localizing studies pre-operatively for first time neck explorations is still under debate, there is no question of their importance for persistent or recurrent PHP that requires re-operation. Localizing studies in these patients have been clearly shown to reduce operating time, avoid unnecessary dissection, reduce morbidity, and improve success rate.

Several modalities have been employed for localization such as ultrasound (US), computed tomography (CT), and magnetic resonance imaging (MRI). The sensitivity of ultrasound for the preoperative detection of parathyroid adenomas has been reported to be 65-90% (1). There are however, limitations to US. Because of the sonolucent appearance of parathyroid adenomas, it is impossible to distinguish an ectopic cervical parathyroid adenoma from a pathologic lymph node. Furthermore, mediastinal parathyroid adenomas are difficult, if not impossible to visualize due to acoustic shadowing from the sternum and clavicles (2). Also, this method is very operator-dependent. MRI has a slightly higher sensitivity of 62.5-94% while CT has a poor sensitivity of only 40-44% (1).

We are using dual-phase single photon emission tomography (SPECT) imaging with technetium 99m sestamibi and visual thyroid subtraction with technetium 99m as pertechnetate. This method can achieve sensitivities of 68-95% and specificities of 75-100% (1). SPECT imaging is dependent on the differential washout of sestamibi between normal thyroid tissue and abnormal parathyroid tissue. Theoretically, sestamibi will washout of normal thyroid tissue much more quickly than it will from abnormal parathyroid tissue. Therefore, SPECT imaging is usually performed immediately and then at 90 and 180 minutes after sestamibi injection. SPECT imaging, however, has several limitations, not the least of which is its inability to provide discrete anatomic detail.

In addition, we will use a control group of patients who have parathyroid adenomas but who have not yet had surgery to test the efficacy of our fusion software.

Our goal is to acquire MRI and SPECT imaging with fiducial markers and utilize fusion software to create a detailed anatomic map of the neck for more accurate localization of the lesion.


Recruitment information / eligibility

Status Terminated
Enrollment 12
Est. completion date August 2008
Est. primary completion date August 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Subjects who are 18 years and over

- subjects who have had a failed parathyroidectomy and now presents with persistent hyperparathyroidism or recurrent hyperparathyroidism

- 6 control patients with parathyroid adenomas who have not yet had surgery will be selected to test the efficacy of the software.

Exclusion Criteria:

- Potential female subjects who are pregnant

- Any potential subject who has an implanted metallic device, stent or staples

- any subject weighing 300lb

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Locations

Country Name City State
United States SUNY Upstate Medical University Syracuse New York

Sponsors (1)

Lead Sponsor Collaborator
State University of New York - Upstate Medical University

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Terminated NCT04589884 - Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment
Completed NCT00569920 - Nausea and Pain Prophylaxis During Thyroid Surgery N/A
Completed NCT04704349 - Latest Imaging SPECT System Evaluation Phase 1 N/A
Completed NCT03747029 - Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study
Completed NCT03640247 - Pain Medications Following Thyroidectomy and Parathyroidectomy Phase 1
Completed NCT03555487 - Clinical Value of 18F-FCH PET in Localizing Parathyroid Lesions: Comparison With MIBI Scan. Phase 3
Completed NCT04344886 - Optimization and Individualization of Diagnostic Scintigraphy Protocol and Minimally Invasive Radio-guided Parathyroid Surgery N/A
Completed NCT03469310 - Minimizing Narcotic Analgesics After Endocrine Surgery Phase 4
Not yet recruiting NCT05243979 - The Relation Between Thyroid , Parathyroid Hormones and eGFR in CKD Patients in Assiut
Active, not recruiting NCT05778071 - Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism Phase 3
Completed NCT02901873 - EIS in Thyroid and Parathyroid Surgery N/A
Recruiting NCT04569513 - The Analysis of Thyroidectomy and Parathyroidectomy
Recruiting NCT05387070 - PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism Phase 3
Not yet recruiting NCT05432050 - Bispectral Index and Patient State Index During General Anesthesia With Remimazolam
Recruiting NCT06274970 - PaThERAS: ERAS Protocols in Thyroid & Parathyroid Surgery N/A
Enrolling by invitation NCT05294393 - Ropivacaine Plus Magnesium Sulphate Infiltration Phase 4
Terminated NCT04745793 - Precise Recognition With Enhanced Vision of Endocrine Neck Targets
Recruiting NCT05152927 - Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy N/A
Active, not recruiting NCT04701203 - A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism Phase 3
Recruiting NCT05022667 - Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy N/A